ORPHA:424080
Undifferentiated carcinoma with osteoclast-like giant cells of pancreas
Also known as: OGCT of pancreas · Osteoclastic giant cell tumor of pancreas · Pancreatic osteoclastic giant cell tumor · Pancreatic undifferentiated carcinoma with osteoclast-like giant cells · Undifferentiated carcinoma of pancreas with osteoclast-like giant cells
Clinical definition (Orphanet)
A rare type of pancreatic ductal adenocarcinoma characterized by composition of non-neoplastic osteoclast-like multinucleated giant cells, a mononuclear histiocytic component, and the neoplastic cells, which vary from spindle-shaped to epithelioid and can be very large and pleomorphic. Clinical features of pancreatic ductal adenocarcinoma include abdominal pain, nausea, weight loss, jaundice, and new-onset diabetes.
How rare: <1 / 1 000 000 — fewer than one in a million. In a city the size of Kolkata, that might mean on the order of fifteen people.
Is anyone studying this?
56
56 papers have ever been published on this condition (under this name). For scale, breast cancer has over 700,000. Median papers in the last 10 years for a rare disease in this dataset (publications denominator n=183) is 38.
56 papers since the earliest indexed year in this search — median last-10-year count for a rare disease in this dataset is 38 (publications denominator n=183).
39 in the last 10 years · high confidence · 51.4th percentile (publications denominator)
Is a treatment being tested?
1
trials for this specific condition
1 interventional trial matched this specific condition name; none in our sample are currently recruiting. 53 trials are registered for undifferentiated carcinoma, the broader category — shown separately because they may or may not enrol this specific subtype.
Data as of 26 July 2026
53
trials for undifferentiated carcinoma, the broader category this belongs to
Trials registered for a broader category may or may not enrol people with this specific subtype — eligibility criteria vary, and the trial record often doesn't say. Worth raising with a clinician. How we count trials.
1 interventional trial — more than 59.2% of diseases in the trials denominator have none at all (151 of 255; this disease is at the 65.3th percentile).
high confidence · 65.3th percentile (trials denominator)
Do we know what causes it?
Not yet — the cause hasn't been pinned down in GenCC.
No strong gene–disease assertion joined for this Orphanet entity.
Who's working on it?
363
Distinct author names in 56 sampled papers — named people below.
Who's working on it?
People publishing on this condition (sampled Europe PMC records). Affiliation is the most recent found in that sample.
- 01Wang X3 papers · 2025
Hongqiao International Institute of Medicine, Tongren Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China. wxy@shsmu.edu.cn.
Papers in Europe PMC - 02Zhang S3 papers · 2022
Liver Research Center, Rhode Island Hospital, Warren Alpert Medical School, Brown University, 55 Claverick Street, 4th Fl., Providence, RI, 02903, USA.
Papers in Europe PMC - 03Capelli P2 papers · 2018
Department of Diagnostics and Public Health, Section of Pathology, University of Verona, Verona, Italy.
Papers in Europe PMC - 04Chen J2 papers · 2022
Department of Radiology, Sir Run Run Shaw hospital, Zhejiang University School of Medicine, Hangzhou City 310016, Zhejiang Province, China.
Papers in Europe PMC - 05Chianchiano P2 papers · 2018
Department of Pathology, Sol Goldman Pancreatic Cancer Research Center, The Johns Hopkins University School of Medicine, Baltimore, MD, USA.
Papers in Europe PMC - 06Jin Y2 papers · 2024
Department of Medical Imaging, National Cancer Center/National Clinical Research Center for Cancer/ Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, 100021, China.
Papers in Europe PMC - 07Kong R2 papers · 2019
Department of Pancreatic and Biliary Surgery; Key Laboratory of Hepatosplenic Surgery, Ministry of Education, The First Affiliated Hospital of Harbin Medical University, Harbin, 150081, Heilongjiang Province, People's Republic of China.
Papers in Europe PMC - 08Li M2 papers · 2022
Immunobiology & Transplant Science Center, Houston Methodist Research Institute, Houston, TX, 77030, USA.
Papers in Europe PMC - 09Luchini C2 papers · 2018
Department of Diagnostics and Public Health, Section of Pathology, University of Verona, Verona, Italy.
Papers in Europe PMC - 10Mafficini A2 papers · 2018
ARC-Net Research Center, University of Verona, Verona, Italy.
Papers in Europe PMC
Recruiting interventional trials
Trials testing a treatment from the matched ClinicalTrials.gov set
1 interventional trials matched after quoted-phrase search and title/condition post-filter.
No currently recruiting studies in the matched set. Open the same search on ClinicalTrials.gov.
Where to find support
We do not yet link condition-specific patient organisations. These umbrella groups support undiagnosed and ultra-rare families:
India — NPRD
Last verified 2026-07-26This ORPHAcode is not on our curated NPRD list (direct or Mondo-parent match). That does not decide clinical eligibility; families in India should ask a notified Centre of Excellence about current coverage.
Hand-curated for this project. ORPHAcode mappings are best-effort and may be incomplete or imprecise for umbrella categories. Parent (Mondo) matches mean the policy lists a broader category — confirm eligibility with a Centre of Excellence. Financial entitlements summarised from public policy statements and may change. This is not official government guidance.
How we counted this
Europe PMC query (preferred label + any corrected label + Orphanet and Mondo exact synonyms, stoplisted; unioned with resolved MeSH labels when available). UMLS / OMIM / NCIT cross-references are stored below but are not added to the query string.
"Undifferentiated carcinoma with osteoclast-like giant cells of pancreas" OR "OGCT of pancreas" OR "Osteoclastic giant cell tumor of pancreas" OR "Pancreatic osteoclastic giant cell tumor" OR "Pancreatic undifferentiated carcinoma with osteoclast-like giant cells" OR "Undifferentiated carcinoma of pancreas with osteoclast-like giant cells" OR "osteoclast-like giant cell neoplasm of pancreas" OR "osteoclast-like giant cell neoplasm of the pancreas" OR "osteoclastic giant cell tumour of pancreas" OR "pancreatic osteoclast-like giant cell carcinoma" OR "pancreatic osteoclastic giant cell tumour" OR "undifferentiated pancreatic carcinoma with osteoclast-like giant cells"
ClinicalTrials.gov query (quoted phrases + MeSH via query.cond, plus recall-expansion terms when used):
"Undifferentiated carcinoma with osteoclast-like giant cells of pancreas" OR "Undifferentiated carcinoma with osteoclast-like giant cells of the pancreas" OR "OGCT of pancreas" OR "OGCT of the pancreas" OR "Osteoclastic giant cell tumor of pancreas" OR "Osteoclastic giant cell tumor of the pancreas" OR "Pancreatic osteoclastic giant cell tumor" OR "Pancreatic undifferentiated carcinoma with osteoclast-like giant cells" OR "Undifferentiated carcinoma of pancreas with osteoclast-like giant cells" OR "Undifferentiated carcinoma of the pancreas with osteoclast-like giant cells" OR "osteoclast-like giant cell neoplasm of pancreas" OR "osteoclast-like giant cell neoplasm of the pancreas" OR "osteoclastic giant cell tumour of pancreas" OR "osteoclastic giant cell tumour of the pancreas" OR "pancreatic osteoclast-like giant cell carcinoma" OR "pancreatic osteoclastic giant cell tumour" OR "undifferentiated pancreatic carcinoma with osteoclast-like giant cells" OR "undifferentiated pancreatic carcinoma"
Interventional trials matched via: phrase (mesh = registered under a MeSH descriptor no name phrase would catch; recall-expansion = gene / selected parent terms used only for trials).
Study-type breakdown: 1 interventional · 0 observational · 0 expanded access. Only interventional studies enter the trial headline.
Cross-references (from Mondo): UMLS:C2007059 NCIT:C5723
Query health: ok — strategies attempted: phrase, recall-expansion; with hits: phrase, recall-expansion
Run this search on ClinicalTrials.gov
Confidence reasoning
- Preferred label is multi-word and distinctive
- No synonyms dropped by stoplist
- No label/synonym collisions with other diseases in this corpus